|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||96.00 - 97.20|
|52 Week Range||62.70 - 116.54|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||1.02%|
Usually, when investors add biotechnology stocks to their portfolios, they feel confident about risk. When they want to reduce risk, biotech names are the first to go. LABU (3X Biotech Bull) and LABD (3X Biotech Bear) can help you stay risk-on or risk-off.
Many institutional traders use multi-faceted strategies that involve several different instruments when trading around an earnings report. Among the most common hedging tools used by institutions are leveraged ETFs, which are built to deliver multiples (or inverse multiples) on a given index. “They aren’t meant to be held for more than a few days at a time,” Sylvia Jablonski, managing director of leveraged ETF provider Direxion ETFs said.
The rising prices of drug treatments, more dependence on immuno-oncology and mergers focused on mid-sized biotech company acquisitions are just a few factors spurning the growth in the biotechnology and pharmaceuticals industry, giving ETFs like Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) exceptional returns. PILL seeks investment results equal to 300% of the daily performance of the Dynamic Pharmaceutical Intellidex Index and concentrates its allocations towards securities of the index and other financial instruments that provide daily leveraged exposure to the index. The index itself just matched a previous high and PILL itself is posting year-to-date returns of 6.36% according to performance figures from Yahoo! Finance.
Since 1997, Direxion has been providing investment solutions with their innovative ETFs and 20 years later, they have $13.4 billion worth of assets under management. If you haven't already, check out the 5 ETFs below that are trending this week - and are worth keeping an eye on during the second half of 2018. Despite all the talk regarding trade wars with the United States and China, one sector that has been shrugging off the market noise is the biotechnology sector.
Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.
Biotechnology stocks and biotech ETFs tumbled in the back half of March and to start April. For example, the SPDR S&P Biotech ETF (NYSEArca: XBI) came into Monday with a loss of almost 12.6% over the past ...
With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.
The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...
Short interest is a popular metric on Wall Street because it gives a peek into the amount of negative sentiment a stock has. For their part, leveraged ETFs thrive on the directionality short interest can ...
December is usually a fine month for stocks, but traders looking to bolster their sector-level returns have some compelling ideas to consider from the world of leveraged exchange traded funds (ETFs). Of ...
The latest Republican tax reform bill takes yet another stab at the Affordable Care Act with a proposed repeal of individual mandates, party leadership said Tuesday . The mandates had required Americans ...
Fast-moving stocks can turn into your biggest winners but come with a larger risk. A half position in a swing trade can get you a low-cost entry to start.